AstraZeneca agreed to buy Pearl Therapeutics, a closely held U.S. drugmaker, for as much as $1.15 billion to expand its portfolio of respiratory-disease treatments as competition for lung medicines increases.
AstraZeneca to pay up to $1.15 billion for Pearl
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You
Sponsored Content